https://scholars.lib.ntu.edu.tw/handle/123456789/633537
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Geyer, C E | en_US |
dc.contributor.author | Garber, J E | en_US |
dc.contributor.author | Gelber, R D | en_US |
dc.contributor.author | Yothers, G | en_US |
dc.contributor.author | Taboada, M | en_US |
dc.contributor.author | Ross, L | en_US |
dc.contributor.author | Rastogi, P | en_US |
dc.contributor.author | CHIUN-SHENG HUANG | en_US |
dc.contributor.author | et al., | en_US |
dc.date.accessioned | 2023-07-12T06:17:43Z | - |
dc.date.available | 2023-07-12T06:17:43Z | - |
dc.date.issued | 2022-12 | - |
dc.identifier.issn | 09237534 | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/633537 | - |
dc.description.abstract | The randomized, double-blind OlympiA trial compared 1 year of the oral poly(adenosine diphosphate-ribose) polymerase inhibitor, olaparib, to matching placebo as adjuvant therapy for patients with pathogenic or likely pathogenic variants in germline BRCA1 or BRCA2 (gBRCA1/2pv) and high-risk, human epidermal growth factor receptor 2-negative, early breast cancer (EBC). The first pre-specified interim analysis (IA) previously demonstrated statistically significant improvement in invasive disease-free survival (IDFS) and distant disease-free survival (DDFS). The olaparib group had fewer deaths than the placebo group, but the difference did not reach statistical significance for overall survival (OS). We now report the pre-specified second IA of OS with updates of IDFS, DDFS, and safety. | en_US |
dc.language.iso | en | en_US |
dc.relation.ispartof | Annals of oncology : official journal of the European Society for Medical Oncology | en_US |
dc.subject | BRCA1/2; PARP inhibition; adjuvant therapy; breast cancer; olaparib | en_US |
dc.title | Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer | en_US |
dc.type | journal article | en |
dc.identifier.doi | 10.1016/j.annonc.2022.09.159 | - |
dc.identifier.pmid | 36228963 | - |
dc.identifier.scopus | 2-s2.0-85141805158 | - |
dc.identifier.url | https://api.elsevier.com/content/abstract/scopus_id/85141805158 | - |
dc.relation.journalvolume | 33 | en_US |
dc.relation.journalissue | 12 | en_US |
dc.relation.pageend | 1268 | en_US |
item.fulltext | no fulltext | - |
item.languageiso639-1 | en | - |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
item.cerifentitytype | Publications | - |
item.openairetype | journal article | - |
item.grantfulltext | none | - |
crisitem.author.dept | Surgery-NTUH | - |
crisitem.author.dept | Surgery | - |
crisitem.author.orcid | 0000-0002-6557-211X | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
Appears in Collections: | 醫學系 |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.